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Abstract
During pancreatic development, transcription factor cascades gradually commit precursor populations to the different
endocrine cell fate pathways. Although mutational analyses have defined the functions of many individual pancreatic
transcription factors, the integrative transcription factor networks required to regulate lineage specification, as well as their
sites of action, are poorly understood. In this study, we investigated where and how the transcription factors Nkx2.2 and
Neurod1 genetically interact to differentially regulate endocrine cell specification. In an Nkx2.2 null background, we
conditionally deleted Neurod1 in the Pdx1+ pancreatic progenitor cells, the Neurog3+ endocrine progenitor cells, or the
glucagon+ alpha cells. These studies determined that, in the absence of Nkx2.2 activity, removal of Neurod1 from the Pdx1+
or Neurog3+ progenitor populations is sufficient to reestablish the specification of the PP and epsilon cell lineages.
Alternatively, in the absence of Nkx2.2, removal of Neurod1 from the Pdx1+ pancreatic progenitor population, but not the
Neurog3+ endocrine progenitor cells, restores alpha cell specification. Subsequent in vitro reporter assays demonstrated
that Nkx2.2 represses Neurod1 in alpha cells. Based on these findings, we conclude that, although Nkx2.2 and Neurod1 are
both necessary to promote beta cell differentiation, Nkx2.2 must repress Neurod1 in a Pdx1+ pancreatic progenitor
population to appropriately commit a subset of Neurog3+ endocrine progenitor cells to the alpha cell lineage. These results
are consistent with the proposed idea that Neurog3+ endocrine progenitor cells represent a heterogeneous population of
unipotent cells, each restricted to a particular endocrine lineage.
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Introduction
The destruction or dysfunction of the insulin-producing beta
cells of the pancreas contributes to a family of metabolic diseases
known as diabetes mellitus. Given that the specification of the
three major cell types in the pancreas, endocrine, exocrine and
ductal cells, occurs in the embryo, understanding the normal
course of pancreas development will ultimately facilitate the
generation of insulin-producing beta cells from alternative cell
sources for beta cell replacement therapies [1,2,3]. Single knockout
mouse models have determined the relative importance of many
transcription factors in the process of endocrine cell specification
and differentiation. Of particular significance, deletion of the basic
helix-loop-helix transcription factor Neurogenin3 (Neurog3; Ngn3)
results in the loss of the hormone-producing cell types [4].
Subsequent lineage tracing experiments confirm that hormone-
expressing endocrine cell types, including alpha cells (expressing
glucagon), beta cells (insulin), delta cells (somatostatin), epsilon
cells (ghrelin), and PP cells (pancreatic polypeptide), are Neurog3-
derived [5,6].
A recent study suggested that each Neurog3+ endocrine
progenitor cell within the population is destined to become a
single hormone+ cell type [7]. The idea that endocrine progenitor
cells are unipotent implies that the transcription factor code
responsible for the differentiation of each hormone+ cell type may
be delineated before endocrine progenitors are specified. In
support of this hypothesis, forced expression of factors within the
Pdx1+ pancreatic progenitor cells can affect the resulting
complement of differentiated endocrine cells [8,9,10]. Ultimately,
the proper timing and location of transcription factor expression
and function during pancreas development is essential for the
appropriate differentiation of all the hormone-expressing endo-
crine cells.
The homeobox transcription factor Nkx2.2 is a particularly
interesting pancreatic regulatory protein due to its dynamic
expression pattern and cell-specific regulatory activities. Nkx2.2
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is widely expressed throughout the early undifferentiated pancre-
atic epithelium, but gradually becomes restricted to beta cells and
a large subset of alpha and PP cells [11,12]. Despite its early and
widespread expression, deletion of Nkx2.2 specifically affects later
endocrine lineage specification: beta cells do not form, alpha and
PP cell numbers are decreased, and there is a significant increase
in the ghrelin cell population. Furthermore, while Nkx2.2 is
expressed in both glucagon+ alpha cells and insulin+ beta cells
[13] and the physical interaction of Nkx2.2 with the co-repressor
Groucho3 (Grg3; Tle3) occurs in both cell types, the recruitment
of a repressor complex to the promoter of the homeobox
transcription factor Arx occurs in beta, but not alpha cells [14],
presumably due to cell-specific and/or promoter-specific protein
interactions. Disruption of the Nkx2.2/Grg3 interaction results in
the mis-specification of islet cell types and the subsequent trans-
differentiation of beta cells into alpha cells [14]. Studies of other
developmental systems, including muscle and CNS, have also
provided examples of how a single transcription factor can
differentially regulate cell specification [15,16,17,18]. Altogether
these studies demonstrate that cell-specific transcription factor
regulation plays a fundamental role in cell fate determination and
the maintenance of cell identity.
While single knockout mouse models can uncover the role of a
specific factor in the process of cell fate determination [19,20,21],
compound deletion mutants demonstrate how multiple transcrip-
tion factors work together to permit or restrict the differentiation
of specific lineages. Whereas the deletion of Arx results in the loss
of alpha cells and an increase in beta and delta cells [19,22],
deletion of Nkx2.2 affects all islet cell types in the pancreas except
the delta cell population [12]. Interestingly, simultaneous deletion
of these two factors revealed for the first time that Nkx2.2 was
required to repress somatostatin in the ghrelin-expressing epsilon
cell lineage [23,24]. Furthermore, the simultaneous deletion of
Nkx2.2 and the beta cell transcription factor Neurod1 identified an
unexpected epistatic relationship between these factors that
regulates the formation of the non-beta cell types [25]. While
deletion of Neurod1 does not affect the formation of alpha or beta
cells, alpha cells are reduced late in development and beta cells
undergo catastrophic apoptosis by birth [26]. In contrast, the null
mutation of Nkx2.2 results in a severe reduction in alpha cells,
and beta cells are completely absent [12,27]. Despite the
expression of Nkx2.2 and Neurod1 in beta cells [13,26,28] and
the severe phenotypes associated with beta cells in both single
knockout mice [12,26], the simultaneous deletion of Neurod1 and
Nkx2.2 did not alter the beta cell phenotype but rather restored
alpha cell and PP cell formation, while simultaneously reducing
the ghrelin-expressing epsilon cells, which are over abundant in
the Nkx2.2 null pancreas [25]. These examples demonstrate that
deciphering the complex pancreatic gene regulatory network will
provide valuable insight into the cellular processes required to
generate each islet cell type, and will facilitate the in vitro
differentiation of functional insulin-producing cells for therapeu-
tic purposes.
The Nkx2.22/2;Neurod12/2 (Nkx2.2null;Neurod1null) compound
mutant provides a useful model for how two transcription factors
coordinately regulate the specification of multiple endocrine cell
types. Our study aimed to dissect the cooperative roles of Nkx2.2
and Neurod1, and determine specifically where and how these
factors work together to permit endocrine cell formation in the
pancreas. The result of this analysis demonstrated that in the
absence of Nkx2.2, deletion of Neurod1 in the Pdx1+ pancreatic
progenitors resulted in restoration of the alpha, PP and epsilon
cells; however, deletion of Neurod1 from the Neurog3+ endocrine
progenitor cells restored the PP and epsilon cells, but only a small
population of alpha cells. Using in vitro reporter assays we also
showed that Nkx2.2 repressed Neurod1 in certain cellular contexts.
Consistent with the idea that Neurog3+ cells are unipotent [7], we
hypothesize that Nkx2.2 must repress Neurod1 in the Pdx1+
pancreatic progenitors early in development to appropriately
prime the Neurog3+ endocrine progenitor cells to become alpha
cells.
Results
In the absence of Nkx2.2, Neurod1 deletion in Pdx1+
pancreatic progenitors recapitulates the Nkx2.2null;
Neurod1null double-knockout phenotype
To determine the precise cell type in which the genetic
interaction between Nkx2.2 and Neurod1 is required for
endocrine cell specification, we conditionally removed Neurod1
from different pancreatic cell populations in the absence of
Nkx2.2. We generated a pancreas-specific deletion of
Neurod1 in the Nkx2.2 null background using Pdx1-cre [29]
(Nkx2.22/2;Neurod1flox/flox;Pdx1-cre, denoted as Nkx2.2null;
Neurod1Dpanc). We first confirmed that the single deletion of Neurod1
in the Pdx1+ cells (Neurod1Dpanc) phenocopied the Neurod1null mouse
(Figure 1B, 1F, 1J; Figure S1), displaying the expected reduction in
insulin and glucagon mRNA levels at P0 (Figure 1M; Figure S1)
[26,30]. We also demonstrated that when Neurod1 was deleted
from Pdx1+ cells in the absence of Nkx2.2, the pancreas
phenotype was identical to the Nkx2.2null;Neurod1null mouse [25]
(Figure S1). Specifically, all beta cells were absent, alpha and PP
cells were restored, and epsilon cells, which were overabundant in
the Nkx2.2null, were significantly reduced (Figure 1A–1L; Figure
S1). The partial rescue of the epsilon cells is likely due to the
inability of Neurod1 deletion to restore the balance between the
epsilon and beta cell populations, similar to the Nkx2.2null;Neur-
od1null mice (Figure 1N; Figure S1; [25]). Hormone expression was
quantified using real time PCR and cell numbers were determined
with morphometric analysis; these analyses confirmed that the
Author Summary
Diabetes mellitus is a family of metabolic diseases that can
result from either destruction or dysfunction of the insulin-
producing beta cells of the pancreas. Recent studies have
provided hope that generating insulin-producing cells
from alternative cell sources may be a possible treatment
for diabetes; this includes the observation that pancreatic
glucagon-expressing alpha cells can be converted into
beta cells under certain physiological or genetic condi-
tions. Our study focuses on two essential beta cell
regulatory factors, Nkx2.2 and Neurod1, and demonstrates
how their genetic interactions can promote the develop-
ment of other hormone-expressing cell types, including
alpha cells. We determined that, while Nkx2.2 is required
to activate Neurod1 to promote beta cell formation, Nkx2.2
must prevent expression of Neurod1 to allow alpha cell
formation. Furthermore, the inactivation of Neurod1 must
occur in the earliest pancreatic progenitors, at a stage in
the differentiation process earlier than previously believed.
These studies contribute to our understanding of the
overlapping gene regulatory networks that specify islet
cell types and identify the importance of timing and
cellular context for these regulatory interactions. Further-
more, our data have broad implications regarding the
manipulation of alpha cells or human pluripotent stem
cells to generate insulin-producing beta cells for thera-
peutic purposes.
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observed gene expression and cellular changes were equivalent
between the Nkx2.2null;Neurod1Dpanc and the Nkx2.2null;Neurod1null
(Figure 1M–1O; Figure S1). Moreover, we confirmed that Neurod1
was appropriately deleted in mutants and controls (Figure 1P).
These data demonstrate that in an Nkx2.2 null background the
deletion of Neurod1 in the pancreas progenitors phenocopies the
Nkx2.2null;Neurod1null.
In mice lacking Nkx2.2, removal of Neurod1 from
Neurog3+ endocrine progenitor cells restores relative
ratios of PP and epsilon cells
Given that all hormone-producing endocrine cells are Neurog3-
derived [4,5,6], we hypothesized that the genetic interaction
between Nkx2.2 and Neurod1 would be required within the
Neurog3+ endocrine progenitors to allow for the specification of
Figure 1. Neurod1 deletion in the pancreas progenitors, in an Nkx2.2 null background, phenocopies the Nkx2.2null;Neurod1null double
knockout. Pancreatic tissue from wildtype, Neurod1Dpanc, Nkx2.2null, and Nkx2.2null;Neurod1Dpanc was analyzed by immunofluorescence for expression
of the islet hormones glucagon (gluc), ghrelin (ghr) and insulin (ins) at P0 (A–L; white bar indicates 50 microns; DAPI marks all nuclei). Amylase (amyl)
expression marks exocrine tissue in all genotypes (A–D). The quantitative expression of glucagon (Gcg) (M), ghrelin (Ghr) (N), and pancreatic
polypeptide (Ppy) (O), as well as deletion of Neurod1 (P) was determined by real time PCR using RNA extracted from wildtype, Neurod1Dpanc, Nkx2.2null,
Nkx2.2null;Neurod1Dpanc, and Nkx2.2null;Neurod1null pancreas (P0; N= 3–8). Relative mRNA expression was normalized to the housekeeping gene,
cyclophilinB. Data are represented as mean+/2SEM. * p,0.05; ** p,0.01; *** p,0.001.
doi:10.1371/journal.pgen.1003278.g001
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particular hormone+ cell types. Using the Neurog3-cre allele [31],
we generated an endocrine progenitor cell-specific deletion of
Neurod1 in the Nkx2.2 null background (Nkx2.22/2;
Neurod1flox/flox;Neurog3-cre, denoted as Nkx2.2null;Neurod1Dendo), and
assessed the pancreatic endocrine cell phenotype. To achieve
optimal recombination in the Neurog3-expressing precursor
population, we used the BAC-derived Neurog3-cre allele; Cre is
highly co-expressed with Neurog3 in the embryonic pancreas and
Cre activity is sufficient to lineage-label all pancreatic endocrine
cells in the islet [31]. Importantly, despite the short half-life of
Neurog3 protein, we can detect Cre activity in approximately 75%
of Neurog3-expressing cells (Figure S2B). Similar to the
Nkx2.2null;Neurod1Dpanc and Nkx2.2null;Neurod1null mice, we observed
rescue of PP cells (Figure 2A, 2B), and a large reduction of
ghrelin+ epsilon cells in the Nkx2.2null;Neurod1Dendo compared with
the Nkx2.2null mice (Figure 2C–2H). As seen in the Nkx2.2null;Neur-
od1Dpanc and Nkx2.2null;Neurod1null mice, there was no rescue of the
insulin-producing beta cell population (Figure 2C–2F; Figure S3).
Given this similar phenotype between the Nkx2.2null;Neurod1null,
Nkx2.2null;Neurod1Dpanc and Nkx2.2null;Neurod1Dendo we conclude that
the genetic interaction between Nkx2.2 and Neurod1 is required
in the Neurog3+ cells to permit specification of the PP and epsilon
cell populations.
Neurod1 deletion from Neurog3+ endocrine progenitors,
in an Nkx2.2 null background, is insufficient to restore the
alpha cell population
Changes in the beta, PP and epsilon cell populations were
identical when Neurod1 was deleted from either the pancreatic or
endocrine progenitors in the absence of Nkx2.2. However, in
contrast to the Nkx2.2null;Neurod1Dpanc and the Nkx2.2null;Neurod1null,
the glucagon-expressing alpha cell population was only minimally
restored in the Nkx2.2null;Neurod1Dendo (Figure 3A–3D). Morpho-
metric analysis (Figure 3E) and real time PCR for glucagon
expression (Figure 3F) confirmed this observation. We also
established that the partial rescue was not due to incomplete
deletion of Neurod1 by Neurog3-cre, as Neurod1 was reduced at an
early stage of Neurog3 expression; becoming almost undetectable
in the mutant pancreata by P0 (Figure 3G; Figure S4). Taken
together, these data suggest that the genetic interaction between
Nkx2.2 and Neurod1 in Pdx1+ progenitors, prior to Neurog3+
endocrine progenitor formation, is required for complete alpha
cell formation.
Alpha cells are not recovered with deletion of Neurod1
from the glucagon+ cells, in the absence of Nkx2.2
Data from the Nkx2.2null;Neurod1Dpanc and Nkx2.2null;Neurod1Dendo
clearly demonstrate that Neurod1 must be deleted from the Pdx1+
progenitor population and not the Neurog3+ endocrine progenitor
population to allow for complete rescue of alpha cell formation.
Furthermore, the simultaneous loss of Nkx2.2 and Neurod1 was able
to rescue even the earliest glucagon-expressing cell population; the
number of glucagon-expressing cells was equivalent between the
Nkx2.2null;Neurod1null and wildtype littermate controls at E10.5
(Figure 4A–4D; data not shown), Interestingly, the early glucagon-
expressing cells are known to express low levels of Pdx1 (Figure S5;
[24]). To determine whether the alpha cell restoration was due to
deletion of Neurod1 specifically from this glucagon+ (Pdx1low)
population in the absence of Nkx2.2, we deleted Neurod1 in the
glucagon-expressing cells using Glu-cre [32] (Figure S2C, S2D). In
the Nkx2.22/2;Neurod1flox/flox;Glu-cre (denoted as Nkx2.2null;
Neurod1Dalpha), the complement of all hormone-expressing cells in
the pancreas was phenotypically identical to the Nkx2.2null, as
determined by immunofluorescent analysis of islet cell markers
(Figure 5A–5L; data not shown) and real time PCR for
quantitative hormone expression (Figure 5M–5O; Figure S6).
These results suggest that restoration of alpha cells requires the
deletion of Neurod1 in Pdx1+ progenitors that have not yet
committed to the glucagon-expressing lineage. We hypothesize
that Nkx2.2 represses Neurod1 in the Pdx1+ cells to give rise to
Neurog3+ endocrine progenitor cells that are primed to differen-
tiate into the alpha cell fate.
Neurod1 is expressed in a subset of Neurog3+ cells and
glucagon+ cells
Since Neurod1 is a downstream target of Neurog3 [33,34] and
the Neurod1 single knockout phenotype does not manifest until
the end of gestation [26], it was surprising that manipulation of
Neurod1 within the Neurog3+ endocrine progenitors was not
sufficient to rescue the alpha cell fate in the Nkx2.2 null
background. To begin to reconcile these unexpected results, we
re-examined when and where Neurod1 was expressed during
pancreatic development. It was previously reported that Neurod1 is
expressed at E9.5 in the earliest islet precursors, and is often co-
expressed with glucagon [26]. Using the Neurod1 null mouse, which
has a LacZ insertion into the Neurod1 locus [35], we confirmed the
presence of Pdx1+/Neurod1(beta-gal+) cells and glucagon+/
Neurod1(beta-gal+) cells in the earliest pancreatic domain
(Figure 6A; Figure S7A); however, not all glucagon+ cells were
Neurod1+ (Figure 6A, 6E). Consistent with previous reports [28],
this pattern was also evident at E13.5 (Figure 6B, 6E) during the
stage of pancreas development marked by a major wave of
endocrine cell differentiation referred to as the ‘‘secondary
transition’’ [36].
Neurod1 is expressed throughout the epithelial cord region,
overlapping extensively with the Neurog3+ precursor cells (Figure
S7B, S7C). We used expression of the Neurod1:LacZ allele to
identify Neurod1 (beta-gal+) cells that co-expressed Neurog3 at
E9.5 (Figure 6C) and at E13.5 (Figure 6D). Interestingly, the
overlap of Neurog3 and Neurod1 was not exclusive at either age,
and a subset of Neurog3+ cells did not express Neurod1
(Figure 6F). We also detected Neurod1 (beta-gal+) expression in
a small population of Sox9low cells (Figure S7D–S7F), indicating
that Neurod1 expression can be found in cells that are
transitioning into Neurog3 precursor cells [37]. Taken together
these expression analyses identified heterogeneous populations of
Neurog3+ cells and glucagon+ cells based on their expression of
Neurod1, and may suggest that the presence or absence of
Neurod1 could influence downstream cell fate decisions.
Nkx2.2 represses Neurod1 in alpha cells
Our cumulative data suggest that Nkx2.2 may function to
repress Neurod1 in a subset of Pdx1+ pancreatic progenitor cells to
promote specification of the alpha cell fate. We had previously
determined that Nkx2.2 directly activates the Neurod1 promoter in
beta cells, which is consistent with the beta cell phenotypes of the
single and double knockout mice [12,26,28] (Figure 7A). To
determine whether Nkx2.2 could also repress Neurod1 expression in
other (non-beta) cell contexts, we analyzed the effect of Nkx2.2 on
Neurod1 expression in alpha cells in vitro. Utilizing previously
described Neurod1 promoter deletion constructs [28] we deter-
mined that Nkx2.2 repressed the Neurod1 promoter in alphaTC1
cells, which express Nkx2.2 [28] (Figure 7). Specifically, the
repressive activity of Nkx2.2 mapped to the proximal region of the
Neurod1 promoter, which is retained in the NDD2 promoter
construct (Figure 7B). We also determined that, similar to Nkx2.2-
dependent activation of the Neurod1 promoter in beta cells, Nkx2.2
Regulating the Lineage Potential of Neurog3+ Cells
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repression required the presence of at least one of the three Nkx2.2
binding sites; deletion of either region containing these consensus
elements (promoter constructs NDD3, NDD4) resulted in a loss of
Nkx2.2 repression (Figure 7B).
To begin to understand how Nkx2.2 mediates differential cell
context-specific regulatory activities through the same set of
promoter elements, we assessed the ability of Nkx2.2 to recruit
specific cofactors and/or modified histones to the Neurod1
promoter in alpha versus beta cell lines. We previously demon-
strated that Nkx2.2 preferentially recruits Grg3 and a large co-
repressor complex to the inactive Arx promoter in beta cells, but
this complex was not present on the same promoter region in
alpha cells, where Arx was actively transcribed [14]. Surprisingly,
neither Grg3 nor HDAC1 were recruited to the Neurod1 promoter
in either alpha or beta cell lines (data not shown), suggesting that
Nkx2.2 mediates Neurod1 regulation through an alternative
mechanism. Interestingly however, we determined that histone
H3K4me3 preferentially occupied the Neurod1 promoter in beta
cells, and this differential binding was dependent upon the
phosphorylation state of Nkx2.2 (Figure 7C). Histone
H3K27me3 was not significantly present at the Neurod1 promoter
in either alpha or beta cell lines (Figure 7D). These results suggest
Figure 2. The genetic interaction of Nkx2.2 and Neurod1 is required in the Neurog3+ endocrine cells to specify PP and epsilon cells.
Pancreatic polypeptide-expressing PP cells (A) and ghrelin-expressing epsilon cells (G) were quantified by morphometric analysis, comparing
wildtype, Neurod1Dendo, Nkx2.2null, Nkx2.2null;Neurod1Dendo, Nkx2.2null;Neurod1Dpanc, and Nkx2.2null;Neurod1null at P0. Cell numbers were quantified
relative to total pancreas area and displayed normalized to wildtype. Representative sections stained for ghrelin and insulin illustrate the change in
ghrelin-expressing cells between genotypes, and the absence of insulin-expressing cells the Nkx2.2null and Nkx2.2null;Neurod1Dendo (C–F; white bar
indicates 50 microns; DAPI marks all nuclei). The expression of pancreatic polypeptide (Ppy) (B) and ghrelin (Ghr) (H) was determined for all genotypes
by real time PCR (P0; N= 3–7). Relative mRNA expression was normalized to the housekeeping gene, cyclophilinB. Data are represented as mean+/
2SEM. * p,0.05; ** p,0.01; *** p,0.001.
doi:10.1371/journal.pgen.1003278.g002
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that while Nkx2.2 promotes activation of Neurod1 in beta cells [28],
Nkx2.2 appears to prevent the activation of the Neurod1 promoter
in alpha cells. This finding is consistent with the idea that Nkx2.2
is required to prevent expression of Neurod1 in a subset of Pdx1+
progenitor cells and then maintain this repression in ‘‘alpha-cell
competent’’ Neurog3-expressing cells, and subsequently mature
alpha cells.
Discussion
Single deletion mutants have identified the importance of a
number of transcription factors for the process of endocrine cell
differentiation (reviewed in [38]). Interestingly, very few factors
when deleted affect only one islet cell type. Therefore we can
deduce that each regulatory protein has multiple roles during
development and it is likely that different combinations of these
factors must be simultaneously present or absent within the
endocrine progenitor cells to permit the specification of alpha,
beta, delta, epsilon or PP cells. The generation of compound
deletion mutants would assist in deciphering this combinatorial
transcription factor code. One such example is the regulatory
interaction between Nkx2.2 and the alpha cell transcription factor
Arx; simultaneous deletion revealed that these factors differentially
cooperate to affect the specification of several islet cell lineages
[23,24]. In this current study, we explore the relative roles of
Nkx2.2 and the beta cell transcription factor Neurod1. The single
deletion mutants for Nkx2.2 or Neurod1 display alterations in several
islet cell types [12,26]; however, these mutants are noted for their
severe beta cell phenotypes. In particular, Nkx2.2 and Neurod1
Figure 3. Alpha cells are only minimally restored in the
Nkx2.2null;Neurod1Dendo. Pancreatic tissue was analyzed by immuno-
fluorescence for the presence of glucagon-expressing cells at
P0, comparing wildtype (A), Neurod1Dendo (B), Nkx2.2null (C), and
Nkx2.2null;Neurod1Dendo (D). Amylase expression marks exocrine tissue
in all genotypes (A–D; white bar indicates 50 microns; DAPI marks all
nuclei). Glucagon-expressing alpha cells were quantified by
morphometric analysis, relative to total pancreas area and displayed
normalized to wildtype (E). The expression of glucagon (Gcg) (F) and
Neurod1 (G) was measured by real time PCR using RNA from P0
pancreas for all genotypes (N= 3–7). Relative mRNA expression was
normalized to the housekeeping gene, cyclophilinB. Data are repre-
sented as mean+/2SEM. * p,0.05; ** p,0.01; *** p,0.001.
doi:10.1371/journal.pgen.1003278.g003
Figure 4. Alpha cells are present in the early pancreatic domain
of the Nkx2.2null;Neurod1null double-knockout mouse. Sections
from E10.5 wildtype (A) and Nkx2.2null;Neurod1null (B) embryos were
stained for Pdx1 to identify the pancreatic domain. Adjacent sections
were stained for FoxA and glucagon (gluc), to identify alpha cells in the
early pancreatic domain in both the wildtype (C) and Nkx2.2null;
Neurod1null (D). White bar indicates 50 microns. DAPI marks all nuclei.
doi:10.1371/journal.pgen.1003278.g004
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are necessary for beta cell specification and maintenance,
respectively [12,26]. Interestingly, simultaneous deletion of
Nkx2.2 and Neurod1 did not affect the respective beta cell
phenotypes of the single mutants, but rather identified complex
genetic interactions between these factors for the specification of
alpha, PP and epsilon cells [25]. In this set of experiments, we have
determined the cellular locations of the genetic interactions
between Nkx2.2 and Neurod1, and have uncovered a possible
mechanism for how these transcription factors contribute to the
process of alpha cell specification. Given the increasing number of
Figure 5. Alpha cells are not rescued with deletion of Neurod1 in glucagon+ cells, in the absence of Nkx2.2. Pancreatic tissue from
wildtype, Neurod1Dalpha, Nkx2.2null, and Nkx2.2null;Neurod1Dalpha was analyzed by immunofluorescence for expression of the islet hormones glucagon
(gluc), ghrelin (ghr) and insulin (ins) at P0 (A–L; white bar indicates 50 microns; DAPI marks all nuclei). Amylase (amyl) expression marks exocrine
tissue in all genotypes (A–D). The quantitative expression of glucagon (Gcg) (M), ghrelin (Ghr) (N), and pancreatic polypeptide (Ppy) (O) was determined
by real time PCR using RNA extracted from pancreas (P0; N = 3–7). Relative mRNA expression was normalized to the housekeeping gene, cyclophilinB.
Data are represented as mean+/2SEM. * p,0.05; ** p,0.01; *** p,0.001.
doi:10.1371/journal.pgen.1003278.g005
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studies identifying transdifferentiation between alpha cells and
beta cells [10,14,39], refining our understanding of alpha cell
development may provide insight into the unique relationship
between alpha and beta cells, and ultimately aid in understanding
how beta cells develop in both the normal and diseased state.
Knowing that all endocrine cell types are derived from
Neurog3-expressing cells [5,6], we hypothesized that the genetic
interaction between Nkx2.2 and Neurod1 would be required in
the Neurog3+ endocrine progenitors to specify islet cell fates. In
support of this hypothesis, deletion of Neurod1 from the Neurog3+
endocrine progenitor cells in an Nkx2.2 null background
(Nkx2.2null;Neurod1Dendo) was sufficient to rescue the relative ratios
of the ghrelin-expressing epsilon cells and pancreatic polypeptide-
expressing PP cells when compared to the Nkx2.2 null phenotype.
This demonstrates that the genetic interaction between Nkx2.2
and Neurod1 is required within the Neurog3+ endocrine
progenitor population to permit appropriate specification of the
PP and epsilon cell populations. In contrast, although alpha cells
were completely rescued in the Nkx2.2null;Neurod1Dpanc, we observed
only a minimal restoration of glucagon+ cells in the
Nkx2.2null;Neurod1Dendo, suggesting that alpha cell recovery requires
the genetic interaction between Nkx2.2 and Neurod1 to occur
within the Pdx1+ pancreatic progenitors, prior to Neurog3+
endocrine progenitor cell formation. This finding would support
the concept proposed by Degraz and Herrera [7] that the
Neurog3+ endocrine progenitors represent a heterogeneous
population of unipotential cells that are already committed to
become a single hormone-producing cell fate.
If all Neurog3+ progenitors are indeed unipotent, then how do
we explain rescue of the PP and ghrelin cell ratios that resulted
from manipulating gene expression after the Neurog3+ cells are
formed? It is possible that there are both unipotential and
multipotential endocrine progenitor populations. Alternatively the
‘‘pro-PP’’ or ‘‘pro-ghrelin’’ Neurog3+ populations may retain
more plasticity throughout development. The latter explanation is
consistent with the findings of Johansson et al., [9], which
demonstrated that as development proceeds the progenitor cells
are less competent to produce alpha cells and instead favor the
generation of other endocrine cell types. This would suggest that
although the alpha cell fate decision can be made at multiple
points during development, the ability to generate alpha cells is
most robust in the earliest pancreatic progenitors and becomes
restricted over time. Alternatively, it is possible that later born
progenitors retain a certain degree of plasticity that accounts for
their ability to respond to lineage manipulations after Neurog3+
cell specification has occurred.
The inability to rescue alpha cells by simultaneously removing
Nkx2.2 and Neurod1 from the Neurog3+ precursor population,
suggests that the genetic interaction between Nkx2.2 and Neurod1
is required in the Pdx1+ progenitor population, prior to
acquisition of Neurog3 expression. However, it remains possible
that there is a spectrum of Neurog3-cre activity within a Neurog3+
precursor cell, with Cre-based inactivation reaching its peak in the
middle or late in the lifespan an individual cell. If this were the
case, and the genetic interaction between Nkx2.2 and Neurod1 is
required only early in the lifespan of a Neurog3+ precursor to
rescue alpha cells, then Neurog3-cre activity may occur too late
within this population to affect its differentiation potential.
Although we are unable to resolve the kinetics of Cre activity in
the lifespan of a single cell, we can demonstrate co-expression of
Neurog3, Cre and R26R reporter activity, suggesting that
although Neurog3 protein expression is transient, Cre is present
and active in most of the Neurog3+ population during the time
window when Neurog3 is expressed (Figure S2B). Furthermore,
published lineage studies using this Neurog3-cre allele demonstrated
that all endocrine cells of the islet, including the glucagon-
expressing alpha cells, are labeled by a Cre-dependent R26R:LacZ
reporter [31]. This would suggest that even if alpha cells can only
Figure 6. Neurod1 is expressed in a subset of endocrine progenitor cells. Utilizing the Neurod1:LacZ knock-in allele (Neurod1LacZ/+) and
immunofluorescence on tissues sections from E9.5 and E13.5 embryos, the expression pattern of Neurod1 (marked by beta-galactosidase; beta-gal)
and glucagon (A, B), and Neurod1 and Neurog3 (C, D) was determined. DAPI marks all nuclei. All images are confocal. White bar indicates 50 microns.
Boxes denote area magnified for inset, which are +1.75zoom of lower power image. Top and right rectangular panels represent a Z projection of at
least 10 stack pictures at the level of intersection of the red/green crosshairs. (E) The percentage of each of the populations of glucagon+ cells, or (F)
Neurog3+ cells was quantitated at E9.5 and E13.5. Data are represented as mean+/2SEM.
doi:10.1371/journal.pgen.1003278.g006
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Figure 7. Nkx2.2 represses the Neurod1 promoter in alphaTC1 cells. (A) Schematic representation of the Neurod1 minimal promoter, with the
areas previously identified to be activated by Nkx2.2 denoted with grey boxes. (B) Luciferase activity was assessed in alphaTC1 cells transfected with
Neurod1 promoter constructs (NDfull, NDD2, NDD3, NDD4) in addition to pcDNA3 alone or Nkx2.2. Nkx2.2-dependent activity was determined based
on promoter region deletion. Luciferase activity was determined 48 hours post-transfection. Luciferase readings were normalized to Renilla luciferase
values. (C) H3K4me3 is enriched in alpha and beta cells, although at significantly lower levels in alpha cells. The Nkx2.2 dephosphorylated mutant (S-
11-A) results in a significant increase in H3K4me3 enrichment in alpha cells, comparable to levels observed in beta cell. Conversely, the Nkx2.2
phosphorylation mutant (S-11-D) results in a significant decrease in H3K4me3 in beta cells, comparable to levels in alpha cells. (D) The repressive
H3K27me3 mark is not present on the Neurod1 promoter in alpha or beta cells (n=3). Data was normalized to Gapdh. All data are represented as
mean+/2SEM. * p,0.05.
doi:10.1371/journal.pgen.1003278.g007
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be differentiated from ‘‘young’’ Neurog3+ precursors, there is
sufficient Cre activity at this earliest stage during the lifespan of a
Neurog3+ cell to genetically label the alpha cell population.
Our failure to recover alpha cells by deleting Neurod1 in a
glucagon-expressing population may also be due to the inefficiency
of the Glu-cre allele, especially in Nkx2.2null embryos that have a
severe reduction in alpha cell numbers. However, we detected
similar levels of Glu-cre activity in wildtype and Nkx2.2null
pancreata, which should have been sufficient to permit any
possible alpha cell rescue (Figure S2C–S2D; see Materials and
Methods). Although caveats exist with the use of Cre/lox
technologies, these are currently the best tools available to assess
spatial and temporal protein function.
Interestingly, we do observe some rescue of alpha cells in the
Nkx2.2null; Neurod1Dendo embryos. This could be due to deletion of
Neurod1 in a subset of Neurog3+ progenitors that have not yet
become restricted in their ability to differentiate into alpha cells.
Alternatively, the glucagon-expressing cells recovered in the
Nkx2.2null;Neurod1Dendo may represent alpha cells that form inde-
pendent of Neurog3 function; such an alpha cell population has
been previously documented [40,41]. On the other hand, the
recovered alpha cells may actually represent a distinct subpopu-
lation of glucagon-expressing cells that express Neurod1, which
would be consistent with our identification of a subpopulation of
glucagon+/Neurod1+ cells. While these explanations are not
mutually exclusive, the identification of unique alpha cell markers
and the generation of genetic tools utilizing these markers, would
be necessary to clarify the existence of subpopulations of alpha
cells, as well as the factors involved in the generation of these
distinct populations.
Our findings also suggest that Nkx2.2 must regulate Neurod1
differentially in the Pdx1+ progenitor population in the early
pancreatic epithelium in order to initiate the specification of
different populations of Neurog3-expressing cells. In particular,
the prevention of Neurod1 activation by Nkx2.2 would result in
alpha cell formation, while the activation of Neurod1 by Nkx2.2
results in beta cell formation (Figure 8). This is compatible with
our discovery that not all Neurog3+ cells express Neurod1, and
further supports the idea that the Neurog3+/Nkx2.2+/Neurod1+
cells most likely become beta cells, whereas Neurog3+/Nkx2.2+/
Neurod12 cells would become alpha cells. Ideally, we would test
this hypothesis by quantifying the increase in the number of
Pdx1+/Neurod1+ pancreas progenitors and/or Neurog3+/Neu-
rod1+ endocrine progenitors expected to be observed in the
Nkx2.2null pancreas; however, this analysis is confounded by the
simultaneous loss of the Neurod1+ pro-beta cell progenitor
populations in the Nkx2.2null pancreas. Instead, we used an in vitro
approach to determine whether it was possible for Nkx2.2 to
differentially regulate the Neurod1 promoter in different cellular
contexts. We had previously demonstrated that Neurod1 is activated
by the cooperative binding of Nkx2.2 and Neurog3 specifically in
beta cells [28]. Given the lack of availability of an appropriate
pancreatic progenitor cell line, we reasoned that a genetic
interaction between Nkx2.2 and Neurod1 that was initiated in a
‘‘pro-alpha cell’’ progenitor would be maintained in the mature
alpha cell. We utilized alphaTC1 cells, which express Nkx2.2 [28],
to demonstrate that Nkx2.2 prevents activation of Neurod1 in alpha
cells. Highlighting the complexity of gene regulation, the cell type
specific regulation of Neurod1 by Nkx2.2 appears to function
through a mechanism that is different from Nkx2.2 regulation of
the Arx gene [14]. This may reflect the mechanism by which
Nkx2.2 functions as an activator and a repressor in the same cell
type and/or the presence or absence of cell-specific co-regulatory
proteins. As we gain the molecular tools to study transcriptional
and epigenetic mechanisms in purified primary pancreatic cell
populations, we hope to elucidate the complex regulatory
interactions that are required to form and maintain appropriate
islet-cell specific gene expression.
While the process of endocrine specification likely requires the
concerted action of many factors, our data suggest a mechanism
that involves the differential regulation of Neurod1 by Nkx2.2 in the
Pdx1+ pancreatic progenitor cells to direct the subsequent
endocrine progenitors to become specific islet cell types. The
generation of tools to identify, separate and analyze different
subpopulations of Neurog3+ progenitor cells would conclusively
determine whether each hormone+ endocrine cell type is derived
from a specific unipotent subpopulation of endocrine progenitor
cells, each bearing a unique gene profile.
Using the pancreas as a model system, our study has provided a
prime example of how lineage decisions are established in the
developing epithelium. The cooperative action of multiple
transcription factors within the early progenitor cells can dictate
the fate of subsequent cell lineages. Altering the regulation or
complement of this set of factors within the progenitor populations
can ultimately skew cell lineage specification. These data have
important implications for the current efforts to generate
pancreatic cells in vitro for therapeutic use in diabetic patients.
Understanding the cooperative transcription factor code will make
it possible to initiate the appropriate program in the Pdx1+
pancreatic progenitor cells necessary to correctly prime the
Neurog3+ endocrine progenitor cells and generate pools of
functional, single hormone-expressing islet cell types in vitro.
Materials and Methods
Mice
All experiments involving mice were approved by the Columbia
University Institutional Animal Care and Use Committee and
performed in accordance with the National Institutes of Health
guidelines for the care and use of animals. All mouse strains were
previously generated, and were bred and maintained on an
outbred Black Swiss background (NTac:NIHBS, Taconic). Cell-
specific Neurod1 null mice were generated by intercrossing
Neurod1tm1Kan (Neurod1flox/flox; [42]) and either Tg(Ipf1-cre)1Tuv
(Pdx1-cre; [29]), Tg(Neurog3-cre)C1Able (Neurog3-cre; [31]), or Glu-cre
([32]) mice. Neurod1flox/flox;Pdx1-cre and Neurod1flox/flox;Neurog3-cre
mice died postnatal, similar to the Neurod1 null (data not shown;
[30]). Certain experiments required the use of either Gt(ROSA)26-
Sortm9(CAG-tdTomato)Hze (R26R:Tomato; [43]) or Gt(ROSA)26Sortm1Sor
(R26R:LacZ; [44]) reporter alleles. The Pdx1-cre will delete Neurod1
in all pancreatic progenitor cells; however, the Pdx1 expression
domain also includes a portion of the stomach and the duodenum
[45,46]. We and others have previously reported the early and
relatively non-mosaic activity of the Pdx1-cre allele ([29,47]; Figure
S2A). Previous characterization of the Neurog3-cre allele demon-
strated almost complete co-expression of Neurog3 and Cre and
sufficient Cre activity to lineage label all endocrine cells within an
islet [31]. Consistent with this published analysis, quantification of
cells co-expressing Neurog3 and the LacZ reporter in a Neurog3-
Cre;R26R:LacZ E15.5 embryo indicated 74.82% Cre efficiency
(268 Neurog3+ beta2 gal+/349 total Neurog3+ cells; calculations
were performed as described below (Figure S2B). Similar
assessment of the Glu-cre mice demonstrated that the Glu-cre allele
is active in approximately 30–35% of alpha cells; notably this
degree of activity is unchanged in the Nkx2.2null background,
despite the overall reduction in alpha cell numbers (Figure S2C,
S2D).
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The heterozygous mice (Neurod1flox/+;Pdx1-cre) were crossed to
Nkx2-2tm1Jlr knock-in mice [12] to generate compound heterozy-
gotes. Embryos were collected from timed matings between
Nkx2.2+/2;Neurod1flox/+;Pdx1-cre and Nkx2.2+/2;Neurod1flox/flox or
Nkx2.2+/2;Neurod1flox/+;Neurog3-cre and Nkx2.2+/2;Neurod1flox/flox
or Nkx2.2+/2;Neurod1flox/+;Glu-cre and Nkx2.2+/2;Neurod1flox/flox
mice. Noon on the day of appearance of a vaginal plug was
considered embryonic day (E) 0.5. The experimental genotypes




Neurod1flox/flox;Glu-cre (Neurod1Dalpha), and Nkx2.22/2;
Neurod1flox/flox;Glu-cre (Nkx2.2null;Neurod1Dalpha) were studied.
Litters were assessed at postnatal day (P) 0. For expression
studies, the Neurod1tm1Jle LacZ knock-in (Neurod1LacZ/+ or
Neurod1null) [35] was used (also in combination with the
Nkx2.2null thereby producing Neurod1null;Nkx2.2null double
knockout embryos; DKO), and embryos were assessed at
E9.5, E10.5, E13.5 and P0. All embryo dissections were
carried out in cold PBS, using a dissecting microscope (Leica
MZ8). A portion of each embryonic tail or yolk sac was
detached from the embryo, digested with proteinase K, and
DNA extracted for genotyping purposes. Genotyping was
carried out with standard conditions and primers as previously
described [12,29,31,32,35,42].
Real-time PCR
Pancreas was dissected from each embryo and stored in
RNAlater (Ambion) until RNA was extracted using the NucleoS-
pin RNAII Kit (Clontech). Subsequently, cDNA was made with
equal amounts of RNA for each sample (Superscript III Kit,
Invitrogen, CA). Real time PCR was performed using TaqMan
gene expression assays (Applied Biosystems) for glucagon
(Mm00801712_m1), ghrelin (Mm00445450_m1), somatostatin
(Mm00436671_m1), insulin1 (Mm01950294_s1), insulin2
Figure 8. A proposed model for the involvement of Nkx2.2 and Neurod1 in alpha and beta cell specification. Taking into account both
our in vivo and in vitro data, we propose that specific combinations of transcription factors acting in the progenitor cells within the early pancreatic
epithelium set up the competency of the unipotent endocrine progenitors to become specific islet cell types. Specifically, we propose a model
whereby Nkx2.2 must repress Neurod1 in a Pdx1+ progenitor, and this repression maintained in the Neurog3+ endocrine progenitor, thereby
permitting glucagon-expressing alpha cell specification. Conversely, activation of Neurod1 by Nkx2.2 permits beta cell formation.
doi:10.1371/journal.pgen.1003278.g008
Regulating the Lineage Potential of Neurog3+ Cells
PLOS Genetics | www.plosgenetics.org 11 February 2013 | Volume 9 | Issue 2 | e1003278
(Mm00731595_gH), pancreatic polypeptide (Mm00435889_m1) and
Neurod1 (Mm01280117_m1). CyclophilinB was used as a control
housekeeping gene, and was assayed using a probe and primer set
previously described [25]. A standard two-step real time PCR
program was used for all genes assessed, with an annealing
temperature of 61uC and 40 cycles of amplification (CFX96
RealTime System C1000 Thermal Cycler, Biorad). All gene
expression values were normalized to the internal control gene,
cyclophilinB, and relative quantification was performed using a
standard curve from embryonic age-matched cDNA. Statistical
analyses were conducted with Prism Software (GraphPad
Software, La Jolla, CA) using both the Mann-Whitney test and
the Student t-test. Equivalent results were obtained; t-test results
were reported in all Figures.
Immunofluorescence
Immunofluorescence was performed according to standard
protocols, on E9.5, E10.5, E13.5, E15.5 and P0 whole embryos
that were embedded in OCT, after fixation with 4% PFA and
cryopreservation in 30% sucrose. Transverse frozen sections
(8 mm) were cut and mounted on glass slides. Sections were
stained with rabbit a-ghrelin (1:800; Phoenix Pharmaceuticals,
CA), goat a-ghrelin (1:800; Santa Cruz), guinea pig a-glucagon
(1:1000; Linco/Millipore, MA), guinea pig a-insulin (1:1000;
Millipore), rabbit a-insulin (1:1000; Cell Signaling Technology),
rabbit a-somatostatin (1:200; Phoenix Pharmaceuticals), rabbit a-
pancreatic polypeptide (1:200; Zymed), rabbit a-amylase (1:1000;
Sigma), rabbit a-Pdx1 (1:1000; Millipore), guinea pig a-Pdx1
(1:500; BCBC), rabbit a-Neurog3 (1:500; BCBC), goat a-
Neurog3 (1:500; BCBC), goat a-FoxA (1:1000; Santa Cruz),
rabbit a-sox9 (1:500; Chemicon), and chicken a-beta-galactosi-
dase (1:250; Abcam). Donkey a-guinea pig-Cy2, -Cy3 or -Cy5, a-
rabbit-Cy2 or -Cy3, a-chicken-Cy3, and a-goat Cy2 or -Cy5
secondary antibodies were used (1:400, Jackson ImmunoRe-
search). DAPI (1:1000; Invitrogen) was applied for 30 minutes
following secondary antibody incubation. Images were acquired
on a Leica DM5500 or Leica 510 confocal microscope.
Morphometric analysis was performed by immunostaining every
10th section throughout each embryo (N= 3 or 4 for each
genotype). For quantification of individual hormone-expressing
cells at P0, cell number was assessed versus total pancreas as
defined by amylase area. For quantification of hormone-
expressing cells at E10.5, cell number was assessed versus total
pancreas as defined by Pdx1 area. Pancreas area was calculated
using ImagePro software.
RNA in situ hybridization
RNA in situ hybridization was performed on 8 mm sections
mounted on glass slides as previously described [25] using an
antisense riboprobe transcribed from linearized plasmid. The
riboprobe for Neurod1 was generated from the plasmid
pCS2:MTmNeuroD1 (J. Lee). RNA in situ hybridization was
performed on pancreas tissue sections from Neurod1Dendo and wildtype
littermate controls at E10.5 and Neurog3-cre;R26RLacZ at E15.5.
Luciferase reporter assays
The Neurod1-2.2 kb minimal promoter was fused to the firefly
luciferase open reading frame in the pGL3 Basic vector (Promega).
The alphaTC1 cells were grown in 12-well plates. The design of all
Neurod1 promoter deletion constructs and the transfection condi-
tions were previously described [28]. Firefly luciferase readings
were normalized to Renilla luciferase values. A Student t-test was
performed to determine significance.
Chromatin immunoprecipitation
Point mutations were made to 3xmyc-tagged Nkx2.2 cDNA
using the QuickChange II Site Directed Mutagenesis kit (Agilent
Technologies) with the following primers S-11-A: (FWD) CAA-
CACAAAGACGGGGTTTGCTGTCAAGGACATCTTGGA-
C, (REV) GTCCAAGATGTCCTTGACAGCAAACCCCGT-
CTTTGTGTTG; S-11-D: (FWD) CAACACAAAGACGGG-
GTTTGATGTCAAGGACATCTTGGAC, (REV) GTCCAA-
GATGTCCTTGACATCAAACCCCGTTTTGTGTTG. Wild
type or mutated Nkx2.2 cDNA encoding a triple myc epitope
tag (250 ng) was transfected into betaTC6 or alphaTC1 cells using
X-treme gene HP (Roche) according to manufacturer’s protocol.
Chromatin was prepared using the ChIP-IT express kit (Active
Motif). Immunoprecipitation protocol was modified from Tuteja
et al. [48]. In brief, immunoprecipitation was performed using the
isolated chromatin diluted in ChIP dilution buffer with 5
micrograms of either mouse anti-H3K27me3 (Abcam) or mouse
anti-H3K4me3 (Abcam) antibodies while rotating overnight at
4uC. The following day antibody/chromatin complexes were
pulled down using ChIP grade protein G magnetic beads (Cell
Signaling). After washing, antibody/chromatin complexes were
eluted from the beads and allowed to rotate at room temperature
for 15 minutes. NaCl (5 micromolar) was added to the eluate and
incubated at 65uC overnight. The following day Tris-HCl (1 M,
pH 7.5), EDTA (0.5 M) and proteinase K (10 mg/mL) were
added and allowed to incubate at 37uC for 1 hour. Samples were
then purified using the QIAquick PCR purification kit (Qiagen).
Quantitative analysis of ChIP products was performed using
SYBR Green fluorescence with primers for Gapdh (FWD –
CTCCACGACATACTCAGCACC; REV – TCAACGGCA-
CAGTCAAGGC) or Neurod1 (FWD – AAAGGGTTAATCT-
CTCCTGCGGGT; REV - CATGCGCCATATGGTCTTCC-
CGGT).
Supporting Information
Figure S1 Morphometric and expression analysis of the
Nkx2.2null;Neurod1Dpanc. Glucagon-expressing alpha cells (A), ghre-
lin-expressing epsilon cells (B) and pancreatic polypeptide-
expressing PP cells (C) were quantified by morphometric analysis,
comparing wildtype, Neurod1Dpanc, Nkx2.2null, Nkx2.2null;Neurod1Dpanc,
and Nkx2.2null;Neurod1null at P0. Cell numbers were quantified
relative to total pancreas area and displayed normalized to
wildtype (N= 3–4). The quantitative expression of insulin1 (Ins1)
(D), insulin2 (Ins2) (E), and somatostatin (Sst) (F) was determined by
real time PCR using RNA extracted from wildtype, Neurod1Dpanc,
Nkx2.2null, Nkx2.2null;Neurod1Dpanc, and Nkx2.2null;Neurod1null pancreas
(P0; N= 3–8). Relative mRNA expression was normalized to the
housekeeping gene, cyclophilinB. Data are represented as mean+/
2SEM. * p,0.05; ** p,0.01; *** p,0.001.
(TIF)
Figure S2 Expression analysis in the Pdx1-cre, Neurog3-cre and Glu-
cre alleles. A small population of Neurog3-expressing cells at E12.5
was observed to not co-express beta-gal (A). Individual channels
were separated in side panel to better visualize the Neurog3 cells
that do not express beta-gal. In e15.5 pancreata containing Neurog3-
cre and the R26R;LacZ reporter allele, the majority Neurog3-
expressing cells also express beta-gal, a marker of cre activity (B).
Cells expressing Neurog3, Cre, and beta-gal were also observed,
identifying that both cre expression and cre activity are present
within Neurog3-expressing cells (C; inset). Using the R26R:Tomato
reporter allele, Glu-cre activity was assessed in both the wildtype (D)
and Nkx2.2null;Neurod1Dalpha (E). The glucagon+ cells were not
rescued in this compound mutant, but this was not due to a lack
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of cre activity from the Glu-cre allele. Boxes denote magnified areas
(+1.75zoom of low power image). White bars indicate 50 microns.
(TIF)
Figure S3 Insulin expression in the Nkx2.2null;Neurod1Dendo. The
quantitative expression of insulin1 (Ins1) (A) and insulin2 (Ins2) (B)
was determined by real time PCR using RNA extracted from
wildtype, Neurod1Dendo, Nkx2.2null, and Nkx2.2null;Neurod1Dendo pan-
creas (P0; N= 3–7). Relative mRNA expression was normalized to
the housekeeping gene, cyclophilinB. Data are represented as
mean+/2SEM. * p,0.05; ** p,0.01; *** p,0.001.
(TIF)
Figure S4 Neurod1 inactivation by Neurog3-cre in the early
pancreatic bud. RNA in situ hybridization on pancreas sections
from E10.5 wildtype (A) and Neurod1Dendo (C) embryos
identified a reduction in Neurod1 by Neurog3-cre even at this
early stage of development. Adjacent tissue sections were
stained for Pdx1 (B, D) to identify the pancreas area (encircled
with dashed lines). White bar indicates 50 microns. DAPI
marks all nuclei.
(TIF)
Figure S5 Alpha cells express low levels of Pdx1. A sagittal
section through the dorsal pancreas of a wildtype E10.5 embryo
was stained for Pdx1 and glucagon. Glucagon+ cells were observed
to express low levels of Pdx1. Box denotes area magnified for inset
but was imaged without DAPI; +1.75 zoom of low power image).
White bar indicates 50 microns. DAPI marks all nuclei.
(TIF)
Figure S6 Insulin expression in the Nkx2.2null;Neurod1Dalpha. The
quantitative expression of insulin1 (Ins1) (A) and insulin2 (Ins2) (B)
was determined by real time PCR using RNA extracted from
wildtype, Neurod1Dalpha, Nkx2.2null, and Nkx2.2null;Neurod1Dalpha
pancreas (P0; N= 3–7). Relative mRNA expression was normal-
ized to the housekeeping gene, cyclophilinB. Data are represented as
mean+/2SEM. * p,0.05; ** p,0.01; *** p,0.001.
(TIF)
Figure S7 Neurod1 expression at specific developmental time-
points. Utilizing the Neurod1:LacZ knock-in allele (Neurod1LacZ/+)
and immunofluorescence on tissues sections, Neurod1 (marked by
beta-galactosidase; beta-gal) cells were identified to co-express
Pdx1 at E9.5 (A). The overlap of Neurod1 and Neurog3 expression
was identified at E15.5 by RNA in situ hybridization for Neurod1 (B)
and immunofluorescent staining of Neurog3 (C) on the adjacent
tissue section from a Neurog3-cre;R26R:LacZ embryo. A subset of
Neurod1 cells that co-express Sox9 were also identified at E13.5
(D); the Sox9 (E) and beta-gal (F) channels were separated to
visualize co-expressing cells more clearly. White bars indicate
50 microns. Boxes denote area magnified for inset, which are
+1.75 zoom of lower power image.
(TIF)
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